Upgraded Illumina HiSeq Chemistry
I recently heard a rumor that Illumina is about to introduce a new chemistry that will allow for 2x300bp output. I can't seem to find any more information about it and was wondering if any one else had heard the same thing. I am very interested in learning more about this and would like any information on the topic.
-
-
They have been sitting at 100bp reads for a long time. I would not expect a jump to 300 any time soon. You might have heard about 2x150, or 300 cycle hi seq chemistry.
300bp reads would most likely be on the Miseq first due to the small cycle time. -
They've recently mentioned 2x300bp for the MiSeq in the 2nd half of 2013.Comment
-
MiSeq
With the upgrade they are selling 500 cycle kits to run a 2x250 base run (with index). Haven't run it yet because we are using up our stock of v1 kits first.Comment
-
-
MiSeq not HiSeq
This is for the MiSeq right now-not the HiSeq. I don't think the HiSeq 2500 is going beyond 2 x 150Originally posted by snetmcom View PostComment
-
this thread is about hiseq. which is why i found your note confusing.Originally posted by kwaraska View PostComment
-
FWIW, at the recent Boston Illumina Users' Group Meeting in October, my memory is that 2x150 in rapid mode on the 2500 is the only longer chemistry on HiSeq that was discussed; when queried about 2x150 in standard mode or longer than 2x150 in rapid mode, the Illumina reps were not encouraging speculation that anything like that would be available soon.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment